LONDON, Nov 19 (Reuters) – Swiss drugmaker Novartis on Thursday outlined new mid-term sales targets that were at the lower end of the range it had given a year earlier, ahead of its annual investor event in London. Novartis now expects net sales to grow 5% annually at constant currencies from 2026 through 2031. Previously, […]
Health
Novartis narrows mid-term annual sales growth target to 5% through 2031
Audio By Carbonatix
LONDON, Nov 19 (Reuters) – Swiss drugmaker Novartis on Thursday outlined new mid-term sales targets that were at the lower end of the range it had given a year earlier, ahead of its annual investor event in London. Novartis now expects net sales to grow 5% annually at constant currencies from 2026 through 2031. Previously, the company expected sales growth of 5%-6% through 2030.
Following a string of late-stage study setbacks in September, that drew close scrutiny on CEO Vas Narasimhan’s dealmaking strategy, Novartis is now looking to boost investor confidence in its post-2030 growth plans.
Novartis faces a steep patent cliff with blockbusters like heart drug Entresto seeing tough competition from cheaper rivals, raising the question of how it will sustain growth over the next decade, when another top seller, Cosentyx, will lose exclusivity.
The company expects sales from its anti-inflammatory drug Rhapsido, breast cancer drug Kisqali and multiple sclerosis drug Kesimpta, among others, can offset the drop in sales.
Of these, Rhapsido and Kisqali are expected to bring in peak annual sales of $8 billion and $10 billion each.
New experimental medicines, including ianalumab, abelacimab and del-brax, could add further sales.
(Reporting by Bhanvi Satija and Marleen KaesebierEditing by Dave Graham)

